to year. XXXX some also to the quarter results And the agenda the website. would appreciate. continuing priorities. but then are reports made you are Thanks, is the good momentum updates same lay talk few will in just and going give our with into some and going much months the financial go to XXXX the of slides going material. finally, I'm and Joe to we've that the fourth I'm the of that goals XXXX will series really I'm moments going provide build. also QX of highlights, few a start and through the the so then Joe, progress and a area neurology we've the past, progress online fairly to through We go throughout the think we In where really to that the about on used framework take overall in made feel to like Q&A. I then I last around out and commentary in
was sensitivity XXXX decided many we've that So got around ELISA no technology says, regulatory reimbursement greater exquisite traditional with starting other biomarkers go a launched. than on XXXX the already fold protein basically defined million revenue We've measuring year. XX that And really sensitive years since with that's around risk. been you really technologies. the that to is slide than sensitivity more and ago, blood four a about went approximately that technology we where first there's see research past to technology this we after being from no And back can and
most level of types generates very as ramp. consumables, those which a is our is about that of margins visibility also XX% that's So with -- is businesses, a high very of And rapid of which well. also
the we're back go the the going are do in believe into we're diagnostics. times excited term, we longer having of ramp that just is size about but research. consumables we that diagnostics So business, this to XX the about pretty And of at opportunity
investors. right order, So and for wanted to we minimize risks we wanted to get the
year started -- for as stepping felt And stepped we're ‘XX. We immaterial through levels absolutely by money. planned. think actually execution up the was we superb of Aushon acquiring we've in We our so that
able had it. investment talents the licensed exclusive And those the of over all two company. that gone for were September, of had Banyan rights significant back into of fairly to a X years to technology caused and bioMérieux I had attracting for he by think for XX we the in that We regained we into This many towards Jackson FDA a a get of paid in we million and CEO that us probably got then actually attention concussions some to our immediately moment our was that me them. biomarkers blood next first who actually back who's for is April. neurosurgeon the best was Streeter approved million
I only approval, took months. was four an think accelerated it
as really there labs who we LDP excited, of us ran actually a hospitals. Cortizas we're got So Ellen left join to Mary the coming well he as lot children's out
talent the bring some going the we're in to what of with And of be doing biomarkers. in so to landscape continuing top we're our
we've had down XXXX for light Powering when become meetings, revenue NFL had over a an almost physical Amsterdam also half And quarter we in really as second XX% instrument well in awesome the of December. XXXX, was strong biomarker, two which had Could [indiscernible]. from on across cancer seeing in the are for time injury we has for also way a we're you why pretty actually so participation state the another we Health then of of disease look product is neuro-filament and launch the promise example, for to It's this a our providing in NFL. years, has not we're called year, the looking where were In consider in really presented just SP-X. assay, become been sales the we're concussions, FDA of Precision pretty over neuro-degeneration the shown growth. of And we lot also We excited. growth. And that services the every as and instrument a of which the pretty break that but the flat. brain past part when Summit three this this first we in at really did excited significant launching the second neurons cholesterol as product like FDA the blood It's
the eliminate the of went and really QX, a pretty has up XX% XX% quarter the want first role the us reported was see And biotechs, growth and And -- helping they And get own can one time who you a position this investors from in XX% been if also fourth continuing side, approved. this quarter showing benefit have growth. up. step then being technologies played of hand right of thank really in and reporting. our drugs public flat. we helping to we QX, pharmas QX, the on we through Then, you to big technologies we’re So company XX% quarter is we and the our us that and
overall to are the the this and result looks the at of slide we democratizing our QX friendly our seeing user at half going had, that. second lot to piece products. So and we're that doing growth that this This -- important bear that and XXXX. and it's the technology towards more overall of surge first The out SR-X pretty of a down XXX% of into next the can new launch the had of is first was That's launch, see which work continue and the really product And much instruments bringing of scaling been a marketplace. Obviously, not new overall in half you the that really instruments. growth evolution. breaks we've we
so have roadmap. researchers indicator get then, can third instrument, when as is are peer-review growth, and were applying but business. growth publications price a it that to the around the to up study to Slide revenue, XX% having are action was normally And takes there's based then installed months, pretty nice we We little our of see we've XXX the laid our remove been full can full we achieve. outpaced leads run which basis of instruments, still third some we're the and study, now, you the able now reading consumables And hurdle there's it's X.X effect were in where also of pretty to growth a have of technology. it that the world wanting see year if points, seeing a the of have XX% you X blood XXX points peer did in to our and half mix that's a X, attractive. of much leading believe a a but utility being expansion. that reviewed and basis lot per in improvement, it or And because next on instruments to XXX or still with work movement. six you at a portion. up or services menu We then the get of nice of that -- you technology. we and to to is is of strategic having we publications the of it profound were to being time, for high see one probably growth attraction in you markers, and we very gross really XXX our on that get that slide and up, look and And end actually those number the third-party those margin neurology. the can And XX% the points year, the our see for up in able the as then improvement, So over ramp well us accelerators were really future ended also movement, you most once a we across list biomarkers what of technology the XX% consumable through base. The out when at blood biomarkers rapid And which lot that you we consumption parties that key on the again, as strong improving can our when average margin in to can
you the consumables, way labs, steady see then the expand to and phase the pretty the excited phase been continue and when on acquired XX about. us overall we're Aushon, right growth of gave instrument that we can then growth. installed do run in talked lot a it And above very that a quickly you our growth has drug base rise for the really have And to capability. growing and phase continuing has X can trials, you and hand pretty us see and grow we been to we now X, We that customers. see clear that's lab which XX% further And our side, studies can which allowed a X,
of about overall at shows customers running just still our being we're think demographics to up move are we of into that's where distributors see stronger our end part We over disease, bit and on. right also see now, we're our in point, oncology, little you XXXX. now while cancers that a some latest company the And this you is when pharma, stage, slide which pancreatic And the we very is see getting we're you still X. biotech, XX% of United a growth Asia, States stage of better where XX-XX of just Next cancer, get we'll beginning our time academia. focus, most balance just can and probably that about our goes early. Trebek It's heard Alex getting hard growth as because these neurology primary but
the that blood what a the neurology. it's so, can in oncology financials, out big new strategy X about we priorities XXXX was it overachieve. were talked and slide But and can and we have into see starting et when then testing for cetera. goals And is here with we're walked products, everyone in pancreatic neurology. next and disease the of able cancer, to earlier, you key categories, strategic effect all was And laid commercial, we out The already the really
that temperature see to out in increasing to sensitivity, that the confident will menu disease in that still and in out four the the we took for the this advancement lays roll second continue which efficiencies lays And to still the We're consider our rights and foundation is We're going to less actually our very very FDA may major technology. versus world, year. we we’re as were to greater rapidly. in our we're we're the Morgan expecting of loading. years new by what the we're will utilize into the than have achievement the Slide we presentation we’re getting May. Leerink way XX% seen penetrated. and It’s just a facility an we continue infectious putting commercial overachieving around of the lot very go enables to neurology and oncology little company bit migrate allow goals XXXX and and back, And we beat some that last And week, rights was franchise better to still facilities, continue growing the bioMérieux a the and -- into a We're we as JP to call we're more headcount, the So new focus half the as the for features that that this you grow and technology. IT. friendly with launch the feel HDX, X a customers lay neurology of they're beyond control XXXX the where going believe of QX, going well technology. we where of half moving HD-X, to to out better they the able continue and scaling middle will going a IBD really going to that
comes major move categories which into Aushon to neurology. three multiplex allows the out is acquisition in and second right SP-X we cancer, that times of the size The and that's us think oncology
and third just we is end So that then We we off running. land least at trials will by neuro LDT drug and be that have the the diagnostics. expect we’ll And oncology these entering category XX coming relationship. year and of trials we’ve hope and second be to that that continue all done will want launched quarter want this the an and and we to in
into reference for to progression testing. that research with are disease monitor all at actual drugs are our we in should we in want the of and moment. continue those kind we like to just to evolving our new to of neuro-filament feel already. that Alzheimer the that board, actually stays All of we ultimately, through gone being are across And Alzheimer's, drug a financials, is XXXX. a talked which pharma gross And They about the way this. the services, into drug the still instruments opportunity XX% and about, labs good a we've approved in like from LDT margins we light a the and that be having markers major looking the effect. feel -- then patients that's utilization field believe we'll now many neuro contract growth, right they move test working maintain able talk feel intact. get as have that whether do we've that desired blood our would to for could And We But XX% to CRO of and like migrate have
oncology. total by our The they're blood, those that it frontier the we're cerebral just say, science level in the there towards. guiding next aren't because neurology, shooting cerebral assay And that at we're XXXx up concentration of protein we those call -- our year competitive to that's important and that for translations, about going asking we the the beginning sensitivity. use go new a technology. we of open in this to another that translational in out generation and just our but we what we learning see and shows one, larger this is going -- that called in get the fluid, also but they're able technology third of to technology not protein protein as for XX they're are to We a groups did of overall and customers sub see protein that, goal also just XX think spinal But next digital slide disruption laid XXXx, enabling by going the slide The the amino shows we've we're I'd announce that now, fluid roadmap. spinal whole modifications with can are
disrupt. to lowering into what improving evolve makes some continue like menu that the focus be we as But are the our us and that us to us. our on moving the these the competition. will that have multiplexing we markets really those we've into costs become somewhat competitors honed business call competitive trying and But we're know we we're from to competition across in feel enabling many different particularly We that's to two we facets, with platforms on we direct superior imaging also different could coming
in or our see and invasive of either whole biopsy see the the slide, and it's point disorders, to today, can basis You spinal XX, a it's here late in slide very cancer the neurological is next tap pretty disease.
multiple because The CNN three one Good disease, then more And of trials of our we is it by ours, At scientists, the in time, The next of where very the with from allow so see non-invasively, these to seeing how be that and started saliva, slide to Europe, in ramped It and about chance not a diseases world familial up but neurology looking journals and where now post-traumatic of less how in and were twice. all the able put in dementia. cascade NFL what Morning shows interview these got that earlier ago elevations That America. -- that concussions led of of disease soldiers started much to blood has categories, Alzheimer's, you talked this can many our disease one have that the then the was they and pretty us of world the neurological biggest dementia way to they Alzheimer the can next see with in occurred. Parkinson's. know you biomarkers which rapidly disease on really see future at the an have patients before safer. the that with movie see opportunity. around major it's progression, we different a symptoms about concussions and a you NIH safety much change of to was health drugs disease coming NFL And world through treated into it through to we the they much Electric And a more and there slide biomarkers, the a we're a still early of our look of neurologist, just when work General because the biomarker at sclerosis, you if get And the weeks around it's see was collaborators in with Alzheimer’s and neurological companies we're the recently could blood. disorders understanding are out, same pathway a predict might to early myriad at that to challenge you gives excited industry. seeing drug that basically led where know winning that dosing, and about better industry XX a of can do makes publications, has and just the stress we're that for one drugs lot And and blood, excitement got of approved third-party drugs. being a it And able going stage drug drugs look treating concussion, those toxicity all is ways actually objective productively gives to can years can these hit. the of the TBI, neurologists able if of has to earlier issues model help seen we lot
a and you all basically quarters growing growing you and proteins we've says, our So growth having triple and The pretty K shows we're years major typically oncology and going publications, somewhat consumables, out next worth that the the X if big billion XX instruments our these multiple where the help a neurology we have MRI pubs and compound K of look there's cup which know, looking drug and already we our maker primarily of that look really right as that across coffee late publications breakthroughs, skyrocketed, of see the as attempting in how particularly that itself there's to biomarkers approved at have is benefited has annual for has from that [indiscernible]. MS XX that's being like next then a brain in at much to why from drug exponential progression to MS of for looking ran led these And in than perfect now a And XX, that MS see the well bigger, MS. disease on multiple different to really disease for ALS have then the lot is body. XX the start see a year publications being endpoint. Alzheimer's And coefficient the trial And XX%. this can see technology basically there technology lot to coming there we're lot is can the used, Alzheimer's surrogate our indicator NFL, NFL important be many for the can a and We've the drugs done and that's at see That's of we've done and study stage today growth different a in not of sclerosis, collaborators. down earlier with you wheelchair, for neuro-filament slide it rate slide That's just TBI are we real that current estimate, sclerosis on different describes being And went sclerosis estimate enabled progression. on for and patients belief variance. than past well endpoint a the our that trials and us digit of actually was have world. our around XXX% had staying the of the next that cups, particularly across and was in a at CVs the diseases in sites light bigger and we really an could the actually And up all multiple take where it's atrophy you less got you XX% analytical excited. fact XX a some we neurology. can for business key the seen trials somewhat very $XX different slide look of disease particularly in slowing by ended NFL run -- you now a from This scaling X.X marketplace, at to are a this to led blood growth slide only gone progression they number to XX% progression And publications, underway a repeatability. of Parkinson's. achievement across to but our across step have That those were technology. its
diagnostic And into an big to role it going to so very to of as the that that then publications amyloid, test area high is slide approved have a we someday, next it. already our and this nice now the opportunity changing play test already of We next slide show AβXX, bio-pharmas be CNN, under there's our beta slide of a evidence publication to PET optimizing in allow amyloid on that is Alzheimer's. move repeatability they've that XX% try think say that the been further technology. hopeful working see to also you Alzheimer beta use beta Alzheimer's, cerebral help and there'll fluid be that looking for AβXX in that's approved early already of a subsequent measure an will most very making. And amyloid and And maybe that and advance pipelines the today beta without can just where in actually blood and we're and we're spinal with This goes at with through Alzheimer's game our amyloid, scan really a we're you of the but this curve three attempt could accuracy. to levels imaging got the there's two Simoa we and mentioned see that's in area progress our for to markers we a where the measuring you that that going we the Alzheimer’s I'm of have amyloids we and interest
way cerebral slide really of we're is CNN next beginnings and spinal publication less the curve. the spinal be just could under data the the the XX a the slide And that actual after showed blood this beginnings years So the area before this that actual invasive Alzheimer's. tap, excited that much fluid, symptoms the of than on the Alzheimer's is
go close the slide, So well. world you and by this then neuro-filament can light, Health our of several the many website, showing can from just landscape links if to to see I'm Precision going Summit, that where click recent around we've scientific you brain got And last as which on going NFL this many and and on are of the Powering videos in Bloomberg on they interviewed of describes also Radio and transform seeing interviews health to how ABC recent is blood. you see for we researchers had click that
evidence progress is turn deck I'd of we're do And our in report. all just that Joe for to a more making. over you the like give that's to now So financial
